Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.